LONG-TERM ANTICOAGULATION THERAPY IN SECONDARY PREVENTION OF ACUTE CORONARY SYNDROME: HOW TO CHOOSE THE PATIENT?

Abstract

The review tells about challenges of antithrombotic therapy in patients after acute coronary syndrome. The efficacy and safety of long-term administration of anticoagulants (warfarin as well as novel anticoagulants), in addition to standard antiplatelet therapy, is discussed. The focus is on rivaroxaban, low doses of which are officially indicated for the prevention of cardiovascular death and myocardial infarction in patients after acute coronary syndrome occurring with increased values of myocardial injury markers. Clinical characteristics of patients feasible for this treatment approach are considered.

Keywords

• acute coronary syndrome
• anticoagulant treatment
• warfarin
• rivaroxaban